A Study for Efficacy and Safety of Aerobic Exercise Training in the treatment of Pulmonary Arterial Hypertension

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031650

Enrollment

Unknown

Registered

2020-04-06

Start date

2020-06-01

Completion date

Unknown

Last updated

2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension

Interventions

Group 1:Aerobic Exercise Training

Group 2:Non-Aerobic Exercise Training

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Subjects were over 18 years old and diagnosed with PAH, including PAH in who group 1 (diagnosis of idiopathic or familial PAH (including PAH related to appetite inhibitor / toxin use), PAH related to congenital systemic pulmonary shunt, or collagen vascular disease)

Exclusion criteria

Exclusion criteria: 1. Absolute contraindications: (1) Acute myocardial infarction (within 2 days); (2) Uncontrolled unstable angina; (3) Uncontrolled arrhythmia leads to hemodynamic instability; (4) Acute endocarditis; (5) Symptomatic severe coarctation of the aorta; (6) Decompensated heart failure; (7) Acute pulmonary embolism, pulmonary infarction or deep vein thrombosis; (8) Acute myocarditis or pericarditis; (9) Acute aortic dissection; (10) Disabled people have potential safety hazards or can not fully complete the exercise test. 2. Relative contraindications: (1) Stenosis of the left main coronary artery was known; (2) Moderate to severe aortic stenosis was associated with uncertain symptoms; (3) Uncontrolled ventricular tachycardia; (4) Acquired high or complete atrioventricular block; (5) Severe hypertrophic obstructive cardiomyopathy (high pressure difference in resting outflow tract); (6) Recent stroke or transient ischemic attack; (7) Those who are difficult to cooperate with; (8) Resting blood pressure > 200 / 110mmhg; (9) Uncorrected clinical problems such as severe anemia, electrolyte disorders, and hyperthyroidism. 3. WHO group 2 pH / WHO group 3 PH /WHO group 5 pH/WHO group 4.

Design outcomes

Primary

Measure	Time frame
peakVO2;cardiopulmonary exercise test;	—

Secondary

Measure	Time frame
6MWD;Echocardiography;cardiac MRI;WHO FC;QoL;Capography;Borg score;stress echocardiography;NTproBNP;biochemistry;Proteomics, transcriptome;	—

Countries

China

Contacts

Public ContactJiang Rong

Shanghai Pulmonary Hospital

listening39@163.com+86 13795493921

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026